We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Marker Therapeutics Inc | NASDAQ:MRKR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.06 | 1.48% | 4.11 | 4.10 | 4.87 | 4.27 | 4.05 | 4.05 | 10,404 | 21:00:05 |
|
Delaware
(State or other jurisdiction of
incorporation or organization) |
| |
45-4497941
(I.R.S. Employer
Identification Number) |
|
|
Large accelerated filer
☐
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☒
|
| |
Smaller reporting company
☒
|
|
| | | |
Emerging growth company
☐
|
|
| | ||||||||||||||||||||||||||||
Title of each class of securities to be registered
|
| | |
Amount to be
Registered |
| | |
Proposed Maximum
Offering Price per Unit |
| | |
Proposed Maximum
Aggregate Offering Price |
| | |
Amount of
Registration Fee(1) |
| ||||||||||||
Common Stock, par value $0.001 per share
|
| | | |
|
(2)
|
| | | | |
|
(3)
|
| | | | |
|
(3)
|
| | | | | | — | | |
Preferred Stock, par value $0.001 per share
|
| | | |
|
(2)
|
| | | | |
|
(3)
|
| | | | |
|
(3)
|
| | | | | | — | | |
Debt Securities
|
| | | |
|
(2)
|
| | | | |
|
(3)
|
| | | | |
|
(3)
|
| | | | | | — | | |
Warrants
|
| | | |
|
(2)
|
| | | | |
|
(3)
|
| | | | |
|
(3)
|
| | | | | | — | | |
Total
|
| | | |
|
(2)
|
| | | | | | | | | | | | $ | 300,000,000 | | | | | | $ | 32,730 | | |
| | | | | i | | | |
| | | | | 1 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 14 | | | |
| | | | | 20 | | | |
| | | | | 22 | | | |
| | | | | 25 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 28 | | |
|
Cantor
|
| |
RBC Capital Markets
|
|
| | | | | S-i | | | |
| | | | | S-1 | | | |
| | | | | S-4 | | | |
| | | | | S-5 | | | |
| | | | | S-7 | | | |
| | | | | S-9 | | | |
| | | | | S-10 | | | |
| | | | | S-12 | | | |
| | | | | S-16 | | | |
| | | | | S-17 | | | |
| | | | | S-17 | | | |
| | | | | S-17 | | | |
| | | | | S-18 | | |
|
Assumed public offering price per share
|
| | | | | | | | | $ | 2.07 | | |
|
Historical net tangible book value per share as of June 30, 2021
|
| | | $ | 0.76 | | | | | | | | |
|
Increase in as adjusted net tangible book value per share attributable to this offering
|
| | | | 0.38 | | | | | | | | |
|
As adjusted net tangible book value per share after this offering
|
| | | | | | | | | | 1.14 | | |
|
Dilution per share to new investors in this offering
|
| | | | | | | | | $ | 0.93 | | |
|
Cantor
|
| |
RBC Capital Markets
|
|
|
SEC registration fee
|
| | | $ | 32,730 | | |
|
Accounting fees and expenses
|
| | | | * | | |
|
Legal fees and expenses
|
| | | | * | | |
|
Transfer agent fees and expenses
|
| | | | * | | |
|
Trustee fees and expenses
|
| | | | * | | |
|
Printing and miscellaneous expenses
|
| | | | * | | |
|
Total
|
| | | $ | * | | |
| | | | MARKER THERAPEUTICS, INC. | | |||
| | | | By: | | |
/s/ Peter Hoang
Peter Hoang
President and Chief Executive Officer |
|
|
Name
|
| |
Title
|
| |
Date
|
|
|
/s/ Peter Hoang
Peter Hoang
|
| |
President, Chief Executive Officer and Director (Principal Executive Officer)
|
| |
August 10, 2021
|
|
|
/s/ Anthony Kim
Anthony Kim
|
| |
Chief Financial Officer
(Principal Financial and Accounting Officer) |
| |
August 10, 2021
|
|
|
/s/ Frederick Wasserman
Frederick Wasserman
|
| |
Chairman of the Board
|
| |
August 10, 2021
|
|
|
/s/ David Laskow-Pooley
David Laskow-Pooley
|
| |
Director
|
| |
August 10, 2021
|
|
|
/s/ John Wilson
John Wilson
|
| |
Director
|
| |
August 10, 2021
|
|
|
/s/ Juan Vera
Juan Vera
|
| |
Director
|
| |
August 10, 2021
|
|
|
/s/ N. David Eansor
N. David Eansor
|
| |
Director
|
| |
August 10, 2021
|
|
|
/s/ Steve Elms
Steve Elms
|
| |
Director
|
| |
August 10, 2021
|
|
1 Year Marker Therapeutics Chart |
1 Month Marker Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions